Archive

Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement

NASDAQ, TSX: NVCN   VANCOUVER and MINNEAPOLIS, May 26, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering...

Read More

Neovasc Provides Corporate Update

NASDAQ, TSX: NVCN   Company outlines milestone achievements towards value creation   VANCOUVER and MINNEAPOLIS, May 26, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces First Quarter Financial Results

Promotes John Panton to Chief Quality Officer   NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, May 7, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...

Read More

Neovasc to Report First Quarter Financial Results on May 7, 2020

NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, April 23, 2020 – Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for...

Read More

Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results

NASDAQ, TSX: NVCN Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results   VANCOUVER and MINNEAPOLIS, March 30, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the TiaraTM (“Tiara”), and minimally...

Read More